KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities: 2018-2024

Historic Total Non-Current Liabilities for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $162.1 million.

  • Aurinia Pharmaceuticals' Total Non-Current Liabilities rose 1.80% to $162.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $162.1 million, marking a year-over-year increase of 1.80%. This contributed to the annual value of $162.1 million for FY2024, which is 1.80% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Total Non-Current Liabilities of $162.1 million as of Q4 2024, which was up 7.67% from $150.5 million recorded in Q3 2024.
  • Aurinia Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $162.1 million for Q4 2024, and its period low was $28.9 million during Q1 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Total Non-Current Liabilities had a median value of $146.4 million in 2023 and averaged $108.3 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Total Non-Current Liabilities plummeted by 39.06% in 2021, and later soared by 251.66% in 2023.
  • Aurinia Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $39.6 million in 2020, then grew by 21.88% to $48.3 million in 2021, then climbed by 10.25% to $53.2 million in 2022, then surged by 199.10% to $159.2 million in 2023, then rose by 1.80% to $162.1 million in 2024.
  • Its last three reported values are $162.1 million in Q4 2024, $150.5 million for Q3 2024, and $148.0 million during Q2 2024.